Search results
Results From The WOW.Com Content Network
By Blake Brittain (Reuters) - Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of Roche's blockbuster rheumatoid ...
Dispiriting news about its investigational obesity drug was the culprit; disseminating this, investors sold out of the pharmaceutical veteran. At the end of the day's action, Roche had lost almost ...
Roche has a new GLP-1 weight loss drug in the works -- and one very cheap stock. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 more ways to reach ...
Roche Molecular Systems, Inc., 563 U.S. 776 (2011), was a United States Supreme Court case in which the Court held that title in a patented invention vests first in the inventor, even if the inventor is a researcher at a federally funded lab subject to the 1980 Bayh–Dole Act. [1]
Roche shares were trading 3.5% down by 0940 GMT, the second biggest faller on the pan-European STOXX 600 index, after the company presented details on the trial with once-daily pill CT-996 late on ...
Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road.
Roche on Friday announced another extension of its $4.3 billion offer for gene therapy specialist Spark Therapeutics, this time until June 3, saying a review by U.S. authorities is taking longer ...
(Reuters) -Roche shares gained as much as 4.7% on Thursday after an early-stage trial showed that a newly-acquired obesity drug candidate led to significant weight loss, a key step in Swiss ...